Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000886163-25-000051
Filing Date
2025-08-08
Accepted
2025-08-08 16:12:04
Documents
72
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q lgnd-20250630.htm   iXBRL 10-Q 1320518
2 EX-31.1 lgnd_63025exhibit311.htm EX-31.1 15005
3 EX-31.2 lgnd_63025exhibit312.htm EX-31.2 15275
4 EX-32.1 lgnd_63025exhibit321.htm EX-32.1 11040
10 lgnd-20250630_g1.jpg GRAPHIC 43732
  Complete submission text file 0000886163-25-000051.txt   8711636

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20250630.xsd EX-101.SCH 59238
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lgnd-20250630_cal.xml EX-101.CAL 109637
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lgnd-20250630_def.xml EX-101.DEF 341160
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20250630_lab.xml EX-101.LAB 832134
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20250630_pre.xml EX-101.PRE 572625
74 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20250630_htm.xml XML 1212116
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33093 | Film No.: 251198540
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)